{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:20:08Z","timestamp":1793622008007,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pediatric high-grade gliomas are among the deadliest of childhood cancers due to limited knowledge of early driving events in their gliomagenesis and the lack of effective therapies available. In this study, we investigate the oncogenic role of PPM1D, a protein phosphatase often found truncated in pediatric gliomas such as DIPG, and uncover a synthetic lethal interaction between\n                    <jats:italic>PPM1D<\/jats:italic>\n                    mutations and nicotinamide phosphoribosyltransferase (NAMPT) inhibition. Specifically, we show that mutant PPM1D drives hypermethylation of CpG islands throughout the genome and promotes epigenetic silencing of nicotinic acid phosphoribosyltransferase (NAPRT), a key gene involved in NAD biosynthesis. Notably,\n                    <jats:italic>PPM1D<\/jats:italic>\n                    mutant cells are shown to be sensitive to NAMPT inhibitors in vitro and in vivo, within both engineered isogenic astrocytes and primary patient-derived model systems, suggesting the possible application of NAMPT inhibitors for the treatment of pediatric gliomas. Overall, our results reveal a promising approach for the targeting of\n                    <jats:italic>PPM1D<\/jats:italic>\n                    mutant tumors, and define a critical link between oncogenic driver mutations and NAD metabolism, which can be exploited for tumor-specific cell killing.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-11732-6","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T06:02:39Z","timestamp":1566453759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["PPM1D mutations silence NAPRT gene\u00a0expression and confer NAMPT inhibitor sensitivity in glioma"],"prefix":"10.1038","volume":"10","author":[{"given":"Nathan R.","family":"Fons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjini K.","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind N.","family":"Kalathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4593-4096","authenticated-orcid":false,"given":"Mark S.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-426X","authenticated-orcid":false,"given":"\u00c1ngel M.","family":"Carcaboso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Nazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-6787","authenticated-orcid":false,"given":"Michael E.","family":"Berens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4955-3226","authenticated-orcid":false,"given":"Charles","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3255-0467","authenticated-orcid":false,"given":"Ranjit S.","family":"Bindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"11732_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10555-008-9127-x","volume":"27","author":"X Lu","year":"2008","unstructured":"Lu, X. et al. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastas-. Rev. 27, 123\u2013135 (2008).","journal-title":"Cancer Metastas-. Rev."},{"key":"11732_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/ng894","volume":"31","author":"DV Bulavin","year":"2002","unstructured":"Bulavin, D. V. et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31, 210 (2002).","journal-title":"Nat. Genet."},{"key":"11732_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng888","volume":"31","author":"J Li","year":"2002","unstructured":"Li, J. et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet. 31, 133 (2002).","journal-title":"Nat. Genet."},{"key":"11732_CR4","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1158\/1078-0432.CCR-08-2403","volume":"15","author":"DSP Tan","year":"2009","unstructured":"Tan, D. S. P. et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin. Cancer Res. 15, 2269 (2009).","journal-title":"Clin. Cancer Res."},{"key":"11732_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1947601910371979","volume":"1","author":"W Hu","year":"2010","unstructured":"Hu, W. et al. Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1, 360\u2013368 (2010).","journal-title":"Genes Cancer"},{"key":"11732_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11060-007-9470-8","volume":"86","author":"RC Castellino","year":"2008","unstructured":"Castellino, R. C. et al. Medulloblastomas overexpress the p53-inactivating oncogene WIP1\/PPM1D. J. Neuro-Oncol. 86, 245\u2013256 (2008).","journal-title":"J. Neuro-Oncol."},{"key":"11732_CR7","first-page":"1876","volume":"63","author":"F Saito-Ohara","year":"2003","unstructured":"Saito-Ohara, F. et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63, 1876 (2003).","journal-title":"Cancer Res."},{"key":"11732_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 46, 444 (2014).","journal-title":"Nat. Genet."},{"key":"11732_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor, K. R. et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet. 46, 457 (2014).","journal-title":"Nat. Genet."},{"key":"11732_CR10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/ng.2995","volume":"46","author":"L Zhang","year":"2014","unstructured":"Zhang, L. et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat. Genet. 46, 726 (2014).","journal-title":"Nat. Genet."},{"key":"11732_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1083\/jcb.201210031","volume":"201","author":"P Kleiblova","year":"2013","unstructured":"Kleiblova, P. et al. Gain-of-function mutations of PPM1D\/Wip1 impair the p53-dependent G1 checkpoint. J. Cell Biol. 201, 511 (2013).","journal-title":"J. Cell Biol."},{"key":"11732_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nchembio.1427","volume":"10","author":"AG Gilmartin","year":"2014","unstructured":"Gilmartin, A. G. et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat. Chem. Biol. 10, 181 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"11732_CR13","doi-asserted-by":"publisher","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","volume":"9","author":"PL Sulkowski","year":"2017","unstructured":"Sulkowski, P. L. et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med. 9, eaal2463 (2017).","journal-title":"Sci. Transl. Med."},{"key":"11732_CR14","first-page":"7436","volume":"63","author":"M Hasmann","year":"2003","unstructured":"Hasmann, M. & Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436\u20137442 (2003).","journal-title":"Cancer Res."},{"key":"11732_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.nutr.28.061807.155443","volume":"28","author":"KL Bogan","year":"2008","unstructured":"Bogan, K. L. & Brenner, C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev. Nutr. 28, 115\u2013130 (2008).","journal-title":"Annu Rev. Nutr."},{"key":"11732_CR16","doi-asserted-by":"publisher","first-page":"e201301012","DOI":"10.5936\/csbj.201301012","volume":"4","author":"SA Trammell","year":"2013","unstructured":"Trammell, S. A. & Brenner, C. Targeted LCMS-based metabolomics for quantitative measurement of NAD+ metabolites. Comput. Struct. Biotechnol. J. 4, e201301012 (2013).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"11732_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","volume":"22","author":"C Canto","year":"2015","unstructured":"Canto, C., Menzies, K. J. & Auwerx, J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22, 31\u201353 (2015).","journal-title":"Cell Metab."},{"key":"11732_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0092-8674(04)00416-7","volume":"117","author":"P Bieganowski","year":"2004","unstructured":"Bieganowski, P. & Brenner, C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117, 495\u2013502 (2004).","journal-title":"Cell"},{"key":"11732_CR19","doi-asserted-by":"publisher","first-page":"5872","DOI":"10.1128\/MCB.00112-09","volume":"29","author":"M Watson","year":"2009","unstructured":"Watson, M. et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol. 29, 5872\u20135888 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"11732_CR20","doi-asserted-by":"crossref","unstructured":"Olesen U. H., Thougaard A. V., Jensen P. B. & Sehested M. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol. Cancer Ther. 9, 1609\u20131617 (2010).","DOI":"10.1158\/1535-7163.MCT-09-1130"},{"key":"11732_CR21","first-page":"2013","volume":"1186","author":"DS Shames","year":"2013","unstructured":"Shames, D. S. et al. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clin. Cancer Res. 1186, 2013 (2013).","journal-title":"Clin. Cancer Res."},{"key":"11732_CR22","doi-asserted-by":"publisher","first-page":"7757","DOI":"10.1038\/s41586-019-1150-2","volume":"569","author":"S Chowdhry","year":"2019","unstructured":"Chowdhry, S. et al. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature 569, 7757 (2019).","journal-title":"Nature"},{"key":"11732_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja, S. et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell 31, 635\u2013652 (2017). e636.","journal-title":"Cancer Cell"},{"key":"11732_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nature05987","volume":"448","author":"SK Ooi","year":"2007","unstructured":"Ooi, S. K. et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448, 714 (2007).","journal-title":"Nature"},{"key":"11732_CR25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nature07107","volume":"454","author":"A Meissner","year":"2008","unstructured":"Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766 (2008).","journal-title":"Nature"},{"key":"11732_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0469-0","volume":"15","author":"A Blattler","year":"2014","unstructured":"Blattler, A. et al. Global loss of DNA methylation uncovers intronic enhancers in genes showing expression changes. Genome Biol. 15, 469 (2014).","journal-title":"Genome Biol."},{"key":"11732_CR27","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.18632\/oncotarget.6538","volume":"7","author":"S Duarte-Pereira","year":"2016","unstructured":"Duarte-Pereira, S. et al. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors. Oncotarget 7, 1973 (2016).","journal-title":"Oncotarget"},{"key":"11732_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay, A. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32, 520\u2013537 (2017).","journal-title":"Cancer Cell"},{"key":"11732_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","volume":"24","author":"S Bender","year":"2013","unstructured":"Bender, S. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660\u2013672 (2013).","journal-title":"Cancer Cell"},{"key":"11732_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","volume":"483","author":"S Turcan","year":"2012","unstructured":"Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479 (2012).","journal-title":"Nature"},{"key":"11732_CR31","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.18632\/oncotarget.1412","volume":"4","author":"S Turcan","year":"2013","unstructured":"Turcan, S. et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget 4, 1729\u20131736 (2013).","journal-title":"Oncotarget"},{"key":"11732_CR32","doi-asserted-by":"publisher","unstructured":"Mueller, S., et al. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma\u2013PNOC003: a report from the Pacific Pediatric Neuro-Oncology Consortium. Int. J. Cancer. https:\/\/doi.org\/10.1002\/ijc.32258 (2019).","DOI":"10.1002\/ijc.32258"},{"key":"11732_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multi dimensional cancer genomics data. Cancer Discov. 2, 401 (2012).","journal-title":"Cancer Discov."},{"key":"11732_CR34","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1\u2013pl1 (2013).","journal-title":"Sci. Signal"},{"key":"11732_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pharmthera.2015.02.004","volume":"151","author":"D Sampath","year":"2015","unstructured":"Sampath, D. et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol. Ther. 151, 16\u201331 (2015).","journal-title":"Pharmacol. Ther."},{"key":"11732_CR36","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1158\/0008-5472.CAN-16-2263","volume":"77","author":"K Tateishi","year":"2017","unstructured":"Tateishi, K. et al. The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion-mediated cytotoxicity. Cancer Res. 77, 4102\u20134115 (2017).","journal-title":"Cancer Res."},{"key":"11732_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/0304-4165(78)90312-4","volume":"543","author":"P Goodwin","year":"1978","unstructured":"Goodwin, P., Lewis, P., Davies, M., Skidmore, C. & Shall, S. The effect of gamma radiation and neocarzinostatin of NAD and ATP levels in mouse leukaemia cells. Biochim. et. Biophys. Acta (BBA)-Gen. Subj. 543, 576\u2013582 (1978).","journal-title":"Biochim. et. Biophys. Acta (BBA)-Gen. Subj."},{"key":"11732_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/15376516.2015.1014080","volume":"25","author":"JM Tarrant","year":"2015","unstructured":"Tarrant, J. M. et al. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid. Toxicol. Mech. Methods 25, 201\u2013211 (2015).","journal-title":"Toxicol. Mech. Methods"},{"key":"11732_CR39","first-page":"4956","volume":"61","author":"Y Sonoda","year":"2001","unstructured":"Sonoda, Y. et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 61, 4956\u20134960 (2001).","journal-title":"Cancer Res."},{"key":"11732_CR40","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822 (2013).","journal-title":"Nat. Biotechnol."},{"key":"11732_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nprot.2007.10","volume":"2","author":"J Montgomery","year":"2007","unstructured":"Montgomery, J., Wittwer, C. T., Palais, R. & Zhou, L. Simultaneous mutation scanning and genotyping by high-resolution DNA melting analysis. Nat. Protoc. 2, 59 (2007).","journal-title":"Nat. Protoc."},{"key":"11732_CR42","first-page":"071696","volume":"M109","author":"S-H Moon","year":"2010","unstructured":"Moon, S.-H. et al. Wildtype p53-induced phosphatase 1 dephosphorylates histone variant \u03b3-H2AX and suppresses DNA double strand break repair. J. Biol. Chem. M109, 071696 (2010).","journal-title":"J. Biol. Chem."},{"key":"11732_CR43","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/bioinformatics\/btr095","volume":"27","author":"L Kamentsky","year":"2011","unstructured":"Kamentsky, L. et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 27, 1179\u20131180 (2011).","journal-title":"Bioinformatics"},{"key":"11732_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep26933","volume":"6","author":"SA Trammell","year":"2016","unstructured":"Trammell, S. A. et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci. Rep. 6, 26933 (2016).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11732-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:48:01Z","timestamp":1671220081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11732-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11732"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11732-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"6 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.B. is the inventor of intellectual property on nicotinamide riboside, which was developed by ChromaDex Inc. C.B. owns equity in ChromaDex and serves as their chief scientific advisor. C.B. is on the scientific advisory board of ChromaDex and Cytokinetics. All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3790"}}